- Medpace (MEDP) demonstrates strong technical momentum, maintaining a 100% “Buy” technical opinion from Barchart.
- Shares are up more than 20% over the past year.
- Valuation remains a concern, with a trailing P/E of 36.35x.
- I maintain a “Hold” stance, recommending existing holders use a stop loss due to high volatility and divergent analyst targets.